- Home
- QTRX vs PVLA Comparison
QTRX vs PVLA Comparison
Compare QTRX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTRX
- PVLA
- Stock Information
- Founded
- QTRX 2007
- PVLA 2015
- Country
- QTRX United States
- PVLA United States
- Employees
- QTRX N/A
- PVLA N/A
- Industry
- QTRX Biotechnology: Laboratory Analytical Instruments
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- QTRX Industrials
- PVLA Health Care
- Exchange
- QTRX Nasdaq
- PVLA Nasdaq
- Market Cap
- QTRX 233.5M
- PVLA 253.2M
- IPO Year
- QTRX 2017
- PVLA N/A
- Fundamental
- Price
- QTRX $5.20
- PVLA $24.13
- Analyst Decision
- QTRX Buy
- PVLA Strong Buy
- Analyst Count
- QTRX 5
- PVLA 7
- Target Price
- QTRX $15.60
- PVLA $46.29
- AVG Volume (30 Days)
- QTRX 676.0K
- PVLA 52.4K
- Earning Date
- QTRX 05-12-2025
- PVLA 05-15-2025
- Dividend Yield
- QTRX N/A
- PVLA N/A
- EPS Growth
- QTRX N/A
- PVLA N/A
- EPS
- QTRX N/A
- PVLA N/A
- Revenue
- QTRX $135,688,000.00
- PVLA N/A
- Revenue This Year
- QTRX N/A
- PVLA N/A
- Revenue Next Year
- QTRX $14.75
- PVLA N/A
- P/E Ratio
- QTRX N/A
- PVLA N/A
- Revenue Growth
- QTRX 7.71
- PVLA N/A
- 52 Week Low
- QTRX $4.05
- PVLA $11.17
- 52 Week High
- QTRX $19.18
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- QTRX 48.92
- PVLA N/A
- Support Level
- QTRX $4.60
- PVLA N/A
- Resistance Level
- QTRX $5.40
- PVLA N/A
- Average True Range (ATR)
- QTRX 0.46
- PVLA 0.00
- MACD
- QTRX 0.08
- PVLA 0.00
- Stochastic Oscillator
- QTRX 64.61
- PVLA 0.00
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.